Carbaglu FDA Approval History
FDA Approved: Yes (First approved March 18, 2010)
Brand name: Carbaglu
Generic name: carglumic acid
Dosage form: Tablets
Company: Orphan Europe
Treatment for: Hyperammonemia
Carbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated for the treatment of hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).
Development timeline for Carbaglu
| Date | Article |
|---|---|
| Mar 18, 2010 | Approval FDA Approves Carbaglu to Treat Condition That Causes Elevated Ammonia Levels |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
